Isis Pharmaceuticals Announces Open-Label Extension Study SHINE in Pediatric SMA Patients
Post date: Jan 23, 2016 8:57:13 PM
October 22, 2015
BY ANNA TAN, RN
Isis Pharmaceuticals, Inc. recently announced the official launch of an open-label extension study, called SHINE, which will be continuing treatment of the same infants and children diagnosed with spinal muscular atrophy (SMA) who had previously participated in Phase III studies ENDEAR and CHERISH. The infants whi had participated in ENDEAR will continue to receive 12mg of investigational product ISIS-SMNRx every 4 months, while those from CHERISH will receive treatment every 6 months. Following the launch of SHINE, Isis will be receiving a milestone payment worth $11 million from Biogen.